SCHEMBL6282134

SCHEMBL6282134

CCCCC(=NNC(=N)N)c1cn(S(=O)(=O)CCCC)c2ccc(Cl)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.37
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
SLC6A9 P48067 2/20 0.31
KDM4E B2RXH2 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
CCR5 P51681 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282132 1.00 HTR6 (0.37) HTR6ALDH1A1MAPTGABRA1GABRG2
SCHEMBL6286315 0.90 PSEN1 (0.34) HTR6ALDH1A1MAPTGABRA1GABRG2
SCHEMBL6286319 0.90 PSEN1 (0.34) HTR6ALDH1A1MAPTGABRA1GABRG2
SCHEMBL6282759 0.90 HTR6 (0.35) HTR6ALDH1A1SLC6A9KDM4EPSEN1
SCHEMBL6282762 0.90 HTR6 (0.35) HTR6ALDH1A1SLC6A9KDM4EPSEN1
SCHEMBL6285141 0.87 HTR6 (0.47) HTR6CA9
SCHEMBL6285147 0.87 HTR6 (0.47) HTR6CA9
SCHEMBL6277928 0.87 PLK1 (0.42) HTR6
SCHEMBL6277929 0.87 PLK1 (0.42) HTR6
SCHEMBL6282819 0.85 SLC6A9 (0.34) HTR6ALDH1A1MAPTSLC6A9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885ALDH1A1 757/4885MAPT 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.